Athersys Inc (NASDAQ:ATHX) stock sees buying activities in the pre-market after the news. The stock has fallen over 16% over the past month.
Major Trigger:
New Publication Provides Further Clarity of MultiStem’s Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications
Key Highlights:
- Athersys Inc announced today that data accumulated from several years of preclinical research was published in the peer-reviewed journal Scientific Reports. The publication describes the findings from extensive in vitro studies investigating the role Multipotent Adult Progenitor Cells (MAPC®), clinically known as MultiStem® (invimestrocel), have in modulating the inflammatory response.
- The report provides evidence of potential mechanisms by which MAPC cells promote regulatory T cell (Treg) differentiation and proliferation and influence their immune-suppressive phenotype. Tregs are important cells in the immune system, responsible for controlling inflammation and tissue repair after injury through several mechanisms.
- Dysregulated inflammatory responses are known to contribute to tissue and organ injury in multiple acute critical care indications, such as stroke, trauma, and acute respiratory distress syndrome (ARDS). Enhancement of endogenous, immunoregulatory mechanisms, including promoting Treg differentiation, proliferation, and phenotypic activity, is one way that MultiStem likely mitigates inflammatory organ injury and promotes recovery following tissue injury.
Key Quote:
“Our work helps us understand how MAPC may induce Tregs in vivo, one of the potential mechanisms by which MAPC can help to reshape the hyperinflammatory response, thereby preventing exacerbated tissue damage,” commented Dr. Alice Valentin-Torres, Senior Scientist and Immunologist at Athersys, and primary author of the article.
Market Reaction
As of 8:32, ATHX stock jumped by 1.42% to $1.43. So far more than 20k shares have exchanged hands.
 Stock a Good Buy After The Recent Correction?){kind=link}